Дозы и схемы применения ацикловира у детей

Международ­ное непатен­тованное на­именование Пероральное применение Внутривенное введение Длительность применения
Ацикловир 200 мг 5 раз в сутки детям старше 2 лет, по 100 мг 5 раз в сутки детям младше 2 лет 5–10мг на кг массы тела в сутки каждые 8 часов в течение 10 дней

Меры профилактики вторичного инфицирования:

- избегать длительного применения антибактериальных препаратов для наружного применения с целью исключения развития бактериальной резистентности;

- избегать загрязнения препаратов для наружного применения:

o тубы с мазями не должны храниться открытыми;

o при нанесении кремов необходимо соблюдать гигиенические процедуры – использование чистых спонжей, удаление остатков крема с поверхности банки.

Требования к результатам лечения

- клиническая ремиссия заболевания;

- восстановление утраченной трудоспособности;

- улучшение качества жизни пациентов с АтД.

Тактика при отсутствии эффекта от лечения

Дополнительное обследование для подтверждения правильности диагноза и выявления наиболее значимых для пациента триггерных факторов.

ПРОФИЛАКТИКА

- постоянный базовый уход за кожей;

- элиминация провоцирующих факторов;

- назначение пробиотиков дополнительно к основному питанию матерей с отягощенным аллергологическим анамнезом (в последние недели беременности) и/или новорожденным с риском развития атопии в течение первых месяцев жизни (А) [87-89].

СПИСОК ЛИТЕРАТУРЫ

1. Кубанова А.А., Прошутинская Д.В., Текучева Л.В., Авдиенко И.Н. Интегральный подход к наружной терапии атопического дерматита. Вестник дерматологии и венерологии 2010; 1; 20–26.

2. Leung T.N., Chow C.M., Chow M.P. et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr (new series) 2013; 18: 96–104.

3. Darsow U., Wollenberg A., Simon D. et al. ETFAD / EADV Eczema Task Force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010, 24: 317–328.

4. Chiang C., Eichenfield L.F. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol 2009; 26: 273–278.

5. Breternitz M., Kowatzki D., Langenauer M. et al. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008; 21: 39–45

6. Guidance on Prescribing. In: British National Formulary No.60. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2010

7. Grimalt R., Mengeaud V., Cambazard F.; Study Investigators’ Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology 2007; 214: 61–67.

8. Szczepanowska J., Reich A., Szepietowski J.C. Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis:a randomized comparative study. Pediatr Allergy Immunol 2008; 19: 614–618.

9. Eberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008; 22: 73–82.

10. Berth-Jones J., Damstra R.J., Golsch S. et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367.

11. Glazenburg E.J., Wolkerstorfer A., Gerretsen A.L. et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol 2009; 20: 59–66.

12. Tan B., Weald D., Strickland I., Friedman P. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15–18.

13. Vocks E., Borelli S., Rakoski J. Climatotherapy in atopic dermatitis. Allergologie 1994; 17: 208–213.

14. Engst R., Vocks E. Hochgebirgsklimatherapie bei Dermatosen und Allergien Wirkmechanismen, Ergebnisse und Einflu¨sse auf immunologische Parameter. Rehabilitation 2000; 39: 215–222.

15. Eberlein B., Gulyas A.F., Schultz K. et al. Domestic allergens and endotoxin in three hospitals offering in-patient rehabilitation for allergiс diseases in the alpine mountain climate of Bavaria – the AURA study. Int J Hyg Environ Health 2009; 212: 21–26.

16. Hoare C., Li Wan Po A., Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191.

17. Wollenberg A., Frank R., Kroth J. et al. Proactive therapy of atopic eczema – an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7: 117–121.

18. 27 Patient UK – Fingertip Units for Topical Steroids. [Online]. (URL www.patient.co.uk/showdoc/27000762) (Accessed 12 February 2007).

19. Devillers A.C., Oranje A.P. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and ⁄ or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006; 154: 579–585.

20. Schnopp C., Holtmann C., Stock S. et al. Topical steroids under wetwrap dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 2002; 204: 56–59.

21. Van der Meer J.B., Glazenburg E.J., Mulder .PG. et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140: 1114–1121.

22. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy 2009; 64: 276–278.

23. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528–537.

24. Walsh P., Aeling J., Huff L., Weston W. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29: 501–503.

25. Queille C., Pommarede R., Saurat J.-H.. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol 1984; 1: 246–253.

26. Charman C., Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21: 193–200.

27. Peserico A., Städtler G., Sebastian M. et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in adddition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801–807.

28. Kawashima M., Tango T., Noguchi T. et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212–1221.

29. Alomar A., Berth-Jones J., Bos J.D. et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151 (Suppl. 70): 3–27.

30. Ruzicka T., Bieber T., Schöpf E. et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997; 337: 816–821.

31. Van Leent E.J., Graber M., Thurston M. et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–809.

32. Reitamo S., Wollenberg A., Schöpf E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136: 999–1006.

33. Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271–277.

34. Wollenberg A., Reitamo S., Girolomoni G. et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742–750.

35. Thaci D., Reitamo S., Gonzalez Ensenat M.A. et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348–1356.

36. Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109:547–555.

37. Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010; 21: 144–156.

38. Bornhövd E.C., Burgdorf W.H., Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. Curr Opin Investig Drugs 2002; 3: 708–712.

39. Lübbe J., Pournaras C.C., Saurat J.H. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000; 201: 249–251.

40. Wetzel S., Wollenberg A. Eczema molluscatum in tacrolimus treated atopic dermatitis. Eur J Dermatol 2004; 14: 73–74.

41. Wahn U., Bos J., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: 1–8.

42. Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt 2003; 54: 432–439.

43. Bornhovd E., Wollenberg A. Topische Immunmodulatoren zur Ekzembehandlung. Allergo J 2003; 12: 456–462.

44. Reitamo S., Ortonne J.P., Sand C. et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005; 152: 1282–1289.

45. Reitamo S., Rissanen J., Remitz A. et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396–398.

46. Queille-Roussel C., Paul C., Duteil L. et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507–513.

47. Arellano F.M., Wentworth C.E., Arana A. et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808–816.

48. Margolis D.J., Hoffstad O., Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007; 214: 289–295.

49. Ring J., Barker J., Behrendt H. et al. Review of the potential photococarcinogenicity of topical calcineurin inhibitors. J Eur Acad Dermatol Venereol 2005; 19: 663–671.

50. Thaci D., Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol 2010; 28: 52–56.

51. Patel R.R., Vander Straten M.R., Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol 2003; 139: 1184–1186.

52. Reitamo S., Mandelin J., Rubins A. et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol 2009; 48: 348–355.

53. Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155–162.

54. Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.

55. Reitamo S., Rustin M., Harper J. et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942–951.

56. Langley R.G., Eichenfield L.F., Lucky A.W. et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol 2008; 25: 301–307.

57. Wollenberg A., Sidhu M.K., Odeyemi I. et al. Economic evaluation of secondary prophylactic treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2008; 159: 1322–1330.

58. Thaci D., Chambers C., Sidhu M. et al. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol 2010; 24: 1040–1046.

59. Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164: 387–395.

60. Mandelin J.M., Remitz A., Virtanen H.M. et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat 2010; 21: 167–170.

61. Mandelin J., Remitz A., Virtanen H.M. et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol 2010; 90: 170–174.

62. Boguniewicz M., Fiedler V.C., Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637–644.

63. Nakagawa H., Etoh T., Ishibashi Y. et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.

64. Luger T., van Leent E.J., Graeber M. et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144: 788–794.

65. Eichenfield L.F., Thaci D., de Prost Y. et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 2007; 11: 3–17.

66. Прошутинская Д.В., Бутарева М.М., Иноятова Л.А. Новые возможности терапии атопического дерматита у детей и взрослых. Вестник дерматологии и венерологии 2013; 3: 78–82.

67. Самцов А.В., Сухарев А.В., Патрушев А.В., Бондарь О.И. Клиническая эффективность, безопасность и переносимость 0,1% мази такролимус при лечении атопического дерматита средней и тяжелой степени тяжести. Вестник дерматологии и венерологии 2012; 2: 71–77.

68. Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами. Эффективная фармакотерапия 2014; 19: 4–10.

69. Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). Механизмы действия. Клиническое применение. Вестник дерматологии и венерологии, 2009; 5: 35–42.

70. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Скин-Кап в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский Аллергологический Журнал 2007; 2: 75–81.

71. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты Российского многоцентрового исследования). Вестник педиатрической фармакологии и нутрициологии 2006; 3 (6): 28–31.

72. Williams H.C., Grindlay D.J. What’s new in atopic eczema? An analysis of the clinical significance of systematic reviews on atopic eczema published in 2006 and 2007. Clin Exp Dermatol 2008; 33: 685–688.

73. Gambichler T., Othlinghaus N., Tomi N.S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160: 652–658.

74. Majoie I.M., Oldhoff J.M., van Weelden H. et al. Narrowband ultraviolet B and medium-dose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77–84.

75. Pugashetti R., Lim H.W., Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J Dermatolog Treat2010; 21: 326–330.

76. Tzaneva S., Kittler H., Holzer G. et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol 2010; 162: 655–660.

77. Tominaga M., Tengara S., Kamo A. et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009; 55: 40–46.

78. Горячева Т.А., Самсонов В.А., Надгериева О.В., Волнухин В.А. Клинические результаты узкополосной (311 нм) фототерапии больных атопическим дерматитом. Российский журнал кожных и венерических болезней 2009; 3: 22–25.

79. Авдиенко И.Н., Кубанов А.А. Эффективность дальней длинноволновой ультрафиолетовой терапии у больных атопическим дерматитом. Вестник дерматологии и венерологии 2009; 3: 61–63.

80. Czech W., Brautigam M., Weidinger G., Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653–659.

81. Harper J.I., Ahmed I., Barclay G. et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52–58.

82. Granlund H., Erkko P., Remitz A. et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001; 81: 22–27.

83. Zurbriggen B., Wuthrich B., Cachelin A.B. et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56–60.

84. Darabi K., Hostetler S.G., Bechtel M.A., Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009; 60: 125–136.

85. Lintu P., Savolainen J., Kortekangas-Savolainen O., Kalimo K. Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts. Allergy 2001; 56: 512–517.

86. Mayser P., Kupfer J., Nemetz D. et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream – results of a double-blind, placebo-controlled study. Skin Pharmacol Physiol 2006; 19: 153–159.

87. Panduru М., Panduru N.M., Sălăvăstru C.M., Tiplica G.S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. Journal of the European Academy of Dermatology and Venereology Volume 29, Issue 2, pages 232–242, February 2015

88. Dotterud C.K., Storro O., Johnsen R., Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol 2010; 163: 616–623.\

89. Kim J.Y., Kwon, J.H., Ahn, S.H. et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a doubleblind, randomized, placebocontrolled trial. Pediat Allergy Immunol 2010; 21: 386–393.

Наши рекомендации